213 related articles for article (PubMed ID: 12006555)
21. Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy.
Lee A; Ezzeldin H; Fourie J; Diasio R
Clin Adv Hematol Oncol; 2004 Aug; 2(8):527-32. PubMed ID: 16163233
[TBL] [Abstract][Full Text] [Related]
22. Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity.
Van Kuilenburg AB; Vreken P; Beex LV; Meinsma R; Van Lenthe H; De Abreu RA; van Gennip AH
Eur J Cancer; 1997 Nov; 33(13):2258-64. PubMed ID: 9470816
[TBL] [Abstract][Full Text] [Related]
23. Two cases of 5-fluorouracil toxicity linked with gene variants in the DPYD gene.
Ofverholm A; Arkblad E; Skrtic S; Albertsson P; Shubbar E; Enerbäck C
Clin Biochem; 2010 Feb; 43(3):331-4. PubMed ID: 19822137
[TBL] [Abstract][Full Text] [Related]
24. Lack of large intragenic rearrangements in dihydropyrimidine dehydrogenase (DPYD) gene in fluoropyrimidine-treated patients with high-grade toxicity.
Ticha I; Kleiblova P; Fidlerova J; Novotny J; Pohlreich P; Kleibl Z
Cancer Chemother Pharmacol; 2009 Aug; 64(3):615-8. PubMed ID: 19288105
[TBL] [Abstract][Full Text] [Related]
25. A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy.
Ciccolini J; Mercier C; Evrard A; Dahan L; Boyer JC; Duffaud F; Richard K; Blanquicett C; Milano G; Blesius A; Durand A; Seitz JF; Favre R; Lacarelle B
Ther Drug Monit; 2006 Oct; 28(5):678-85. PubMed ID: 17038885
[TBL] [Abstract][Full Text] [Related]
26. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency.
van Kuilenburg AB; Muller EW; Haasjes J; Meinsma R; Zoetekouw L; Waterham HR; Baas F; Richel DJ; van Gennip AH
Clin Cancer Res; 2001 May; 7(5):1149-53. PubMed ID: 11350878
[TBL] [Abstract][Full Text] [Related]
27. Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy.
Amstutz U; Farese S; Aebi S; Largiadèr CR
J Exp Clin Cancer Res; 2008 Oct; 27(1):54. PubMed ID: 18937829
[TBL] [Abstract][Full Text] [Related]
28. [Severe toxicity after treatment with capecitabine and fluorouracil due to partial dihydropyrimidine dehydrogenase deficiency].
Hooiveld EA; van Kuilenburg AB; Haanen JB; Westermann AM
Ned Tijdschr Geneeskd; 2004 Mar; 148(13):626-8. PubMed ID: 15083629
[TBL] [Abstract][Full Text] [Related]
29. [Detection of DPD exon 14 skipping before fluorouracil treatment].
Steiner M; Schuff-Warner P; Hartung G
Dtsch Med Wochenschr; 2002 Oct; 127(42):2223. PubMed ID: 12397554
[No Abstract] [Full Text] [Related]
30. Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance.
Diasio RB; Johnson MR
Clin Cancer Res; 1999 Oct; 5(10):2672-3. PubMed ID: 10537327
[No Abstract] [Full Text] [Related]
31. Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope?
Ciccolini J; Gross E; Dahan L; Lacarelle B; Mercier C
Clin Colorectal Cancer; 2010 Oct; 9(4):224-8. PubMed ID: 20920994
[TBL] [Abstract][Full Text] [Related]
32. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
[TBL] [Abstract][Full Text] [Related]
33. DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity.
Yang CG; Ciccolini J; Blesius A; Dahan L; Bagarry-Liegey D; Brunet C; Varoquaux A; Frances N; Marouani H; Giovanni A; Ferri-Dessens RM; Chefrour M; Favre R; Duffaud F; Seitz JF; Zanaret M; Lacarelle B; Mercier C
Cancer Chemother Pharmacol; 2011 Jan; 67(1):49-56. PubMed ID: 20204365
[TBL] [Abstract][Full Text] [Related]
34. [Severe 5-fluorouracil toxicity in a woman treated for breast cancer with concurrent osteogenesis imperfecta and dehydrogenase deficiency].
Beuzeboc P; Pierga JY; Lyonnet DS; Couturier J; Pouillart P
Bull Cancer; 1996 Apr; 83(4):324-7. PubMed ID: 8680084
[TBL] [Abstract][Full Text] [Related]
35. Characterization of the human dihydropyrimidine dehydrogenase gene.
Wei X; Elizondo G; Sapone A; McLeod HL; Raunio H; Fernandez-Salguero P; Gonzalez FJ
Genomics; 1998 Aug; 51(3):391-400. PubMed ID: 9721209
[TBL] [Abstract][Full Text] [Related]
36. DPYD*2A mutation: the most common mutation associated with DPD deficiency.
Saif MW; Ezzeldin H; Vance K; Sellers S; Diasio RB
Cancer Chemother Pharmacol; 2007 Sep; 60(4):503-7. PubMed ID: 17165084
[TBL] [Abstract][Full Text] [Related]
37. Predicting fluorouracil toxicity: can we finally do it?
Ezzeldin HH; Diasio RB
J Clin Oncol; 2008 May; 26(13):2080-2. PubMed ID: 18299611
[No Abstract] [Full Text] [Related]
38. [Severe capecitabine-associated toxicity in a patient carrying a mutation in the dihydropyrimidine dehydrogenase gen].
González-Haba E
Farm Hosp; 2012; 36(6):554-5. PubMed ID: 23461455
[No Abstract] [Full Text] [Related]
39. Screening for dihydropyrimidine dehydrogenase deficiency: to do or not to do, that's the question.
van Kuilenburg AB
Cancer Invest; 2006 Mar; 24(2):215-7. PubMed ID: 16537192
[TBL] [Abstract][Full Text] [Related]
40. Severe 5-fluorouracil toxicity caused by reduced dihydropyrimidine dehydrogenase activity due to heterozygosity for a G-->A point mutation.
van Kuilenburg AB; Vreken P; Beex LV; De Abreu RA; van Gennip AH
J Inherit Metab Dis; 1998 Jun; 21(3):280-4. PubMed ID: 9686375
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
